Skip Navigation

JNCI Journal of the National Cancer Institute 1999 91(5):395; doi:10.1093/jnci/91.5.395
© 1999 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Search for Related Content
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Journal of the National Cancer Institute, Vol. 91, No. 5, 395, March 3, 1999
© 1999 Oxford University Press

IN THIS ISSUE

Mechanism of Resistance to Mitoxantrone

Resistance of cancer cells to many anticancer drugs is known to be mediated by P-glycoprotein and multidrug resistance-associated protein (MRP), which are members of the adenosine triphosphate-binding cassette (ABC) superfamily of transporter proteins. However, cancer cells exhibiting resistance to the drug mitoxantrone frequently do not overex-press these proteins. Ross et al. (p. 429) studied expression of the messenger RNA (mRNA) for a recently described member of the ABC transporter family, i.e., breast cancer resistance protein (BCRP), in a variety of mitoxantrone-selected cancer cell lines and found . . . [Full Text of this Article]

Biennial Colorectal Cancer Screening

Fetal Exposure to Cigarette Carcinogens

Analyzing Microarray Data

Interleukin-4 Gene Therapy for Glioma

CDKN2A and Melanoma Risk


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?